IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY (IGAN) explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY (IGAN) trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY (IGAN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to slow kidney disease in IgA nephropathy patients
Disease control Recruiting nowThis study tests a drug called felzartamab in people with IgA nephropathy, a kidney disease where abnormal antibodies build up and damage the kidneys. The goal is to see if felzartamab can lower the amount of protein in urine, a sign of kidney damage. About 454 adults will receiv…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated May 17, 2026 01:50 UTC
-
New drug trial aims to control kidney disease in chinese patients
Disease control Recruiting nowThis study tests a new drug called ADX-038 in 30 Chinese adults with kidney diseases caused by the immune system attacking the kidneys (IgA nephropathy, C3G, or IC-MPGN). The goal is to see if the drug is safe and can help control the disease, either alone or with another medicat…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug zigakibart aims to halt kidney damage in IgA nephropathy
Disease control Recruiting nowThis study tests a drug called zigakibart in 32 adults with IgA nephropathy, a kidney disease. The goal is to see if it can slow disease progression by reducing harmful deposits in the kidneys. Participants will receive the drug and be monitored for changes in kidney function and…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC